Objectives We utilized the database of the Defining Antibiotic Levels in Intensive care unit
patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and …

Purpose To evaluate target attainment of empirically dosed continuous infusion piperacillin/
tazobactam (TZP) and meropenem (MER) in critically ill patients. Patients and methods …

Background Recently, continuous administration of piperacillin-tazobactam has been
proposed as a valuable alternative to traditional intermittent administration especially in …

Objective: Piperacillin-tazobactam is a commonly used antibiotic in critically ill patients;
however, controversy exists as to whether mortality in serious infections can be decreased …

Studies evaluating the outcomes of an extended-infusion (EI) piperacillin-tazobactam dosing
strategy in specific cohorts of critically ill patients are lacking. A retrospective, pre …

Purpose There is variability in the pharmacokinetics (PK) of antibiotics (AB) in critically ill
patients. Therapeutic drug monitoring (TDM) could overcome this variability and increase PK …

Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for
pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in …

Purpose To determine percentage of patients with sub-therapeutic beta-lactam exposure in
our intensive care units (ICU) and to correlate target attainment with clinical outcomes …

Background Beta-lactam anti-infective levels after standard dosing have been shown to be
subtherapeutic when renal clearance is augmented. Objective To determine if piperacillin …

The objective of this study was to evaluate the steady-state pharmacokinetics and
pharmacodynamics of piperacillin/tazobactam, administered by prolonged infusion, in …